• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Old Mutual 2021-2030 Conservative A

Old Mutual 2021-2030 Conservative A

  1. Implanet Announces Its 2016 First-Half Results: Buoyant Growth in Revenue and Substantial Gross Margin Improvement

    Implanet Announces Its 2016 First-Half Results: Buoyant Growth in Revenue and Substantial Gross Margin Improvement

  2. CSI Ranked Second Among World’s Top 100 Cloud Service Providers

    CSI Ranked Second Among World’s Top 100 Cloud Service Providers

  3. ATB-346 Shows Promising Results in Experimental Melanoma

    ATB-346 Shows Promising Results in Experimental Melanoma

  4. Neurovive Pharmaceutical: NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

    Neurovive Pharmaceutical: NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

  5. Phase III Efficacy Results of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced by Exploratory Analyses in Two Forms of Multiple Sclerosis

    Phase III Efficacy Results of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced by Exploratory Analyses in Two Forms of Multiple Sclerosis

  6. IMPLANET: Successful First Surgical Procedures with the New Jazz Lock® Implant

    IMPLANET: Successful First Surgical Procedures with the New Jazz Lock® Implant

  7. Starpharma: VivaGel® Condom Receives Regulatory Approval in Canada

    Starpharma: VivaGel® Condom Receives Regulatory Approval in Canada

  8. Antibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference

    Antibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference

  9. Orexo Completes 1,080 Patient REZOLV Study and Reports on Improved Treatment of Opioid Dependent Patients

    Orexo Completes 1,080 Patient REZOLV Study and Reports on Improved Treatment of Opioid Dependent Patients

  10. Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy

    Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.